JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree
Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.
Therapy Area
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
GSK to file for approval of twice-yearly hep B drug on positive Phase III data
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus
Aktis Oncology kicks 2026 IPO cycle off with $210m target
Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Biogen’s Tysabri to be used on England’s NHS for highly active MS
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus
